The New England journal of medicine, 2017-11, Vol.377 (19), p.1813-1823
- Long, Georgina V
- Hauschild, Axel
- Santinami, Mario
- Atkinson, Victoria
- Mandalà, Mario
- Chiarion-Sileni, Vanna
- Larkin, James
- Nyakas, Marta
- Dutriaux, Caroline
- Haydon, Andrew
- Robert, Caroline
- Mortier, Laurent
- Schachter, Jacob
- Schadendorf, Dirk
- Lesimple, Thierry
- Plummer, Ruth
- Ji, Ran
- Zhang, Pingkuan
- Mookerjee, Bijoyesh
- Legos, Jeff
- Kefford, Richard
- Dummer, Reinhard
- Kirkwood, John M
2017
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Long, Georgina V
- Hauschild, Axel
- Santinami, Mario
- Atkinson, Victoria
- Mandalà, Mario
- Chiarion-Sileni, Vanna
- Larkin, James
- Nyakas, Marta
- Dutriaux, Caroline
- Haydon, Andrew
- Robert, Caroline
- Mortier, Laurent
- Schachter, Jacob
- Schadendorf, Dirk
- Lesimple, Thierry
- Plummer, Ruth
- Ji, Ran
- Zhang, Pingkuan
- Mookerjee, Bijoyesh
- Legos, Jeff
- Kefford, Richard
- Dummer, Reinhard
- Kirkwood, John M
- Titel
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- Ist Teil von
- The New England journal of medicine, 2017-11, Vol.377 (19), p.1813-1823
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2017
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- In patients with surgically resected melanoma, those with BRAF mutations who received 1 year of oral adjuvant therapy with dabrafenib and trametinib had a 53% lower risk of 3-year recurrence than those who received placebo.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1708539Titel-ID: cdi_proquest_journals_1961841348
- Format
- –
- Schlagworte
- Adjuvants, Adjuvants, Immunologic - adverse effects, Adjuvants, Immunologic - therapeutic use, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols - adverse effects, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Cancer therapies, Double-Blind Method, Drug dosages, FDA approval, Female, Humans, Imidazoles - adverse effects, Imidazoles - therapeutic use, Immunotherapy, Inhibitor drugs, Kinases, Male, Medical imaging, Medical prognosis, Melanoma, Melanoma - drug therapy, Melanoma - genetics, Melanoma - mortality, Melanoma - surgery, Melanoma, Cutaneous Malignant, Metastases, Metastasis, Middle Aged, Mutation, Neoplasm Recurrence, Local, Neoplasm Staging, Oncology, Oximes - adverse effects, Oximes - therapeutic use, Proto-Oncogene Proteins B-raf - genetics, Pyridones - adverse effects, Pyridones - therapeutic use, Pyrimidinones - adverse effects, Pyrimidinones - therapeutic use, Skin cancer, Skin Neoplasms - drug therapy, Skin Neoplasms - genetics, Skin Neoplasms - mortality, Skin Neoplasms - surgery, Survival, Survival Analysis, Targeted cancer therapy, Young Adult